The University of Chicago Medicine announced on Thursday the completion of the construction phase of the AbbVie Foundation Cancer Pavilion.
Scheduled to open in April 2027 on UChicago Medicine's main campus in Hyde Park on the South Side, the 575,000-square-foot facility is the state's first and only of its kind dedicated to cancer.
Construction is supported in part by a USD75m donation from the AbbVie Foundation, a nonprofit dedicated to addressing health inequities and accelerating innovative solutions in underserved communities.
The AbbVie Foundation Cancer Pavilion aims to advance the future of cancer medicine while expanding access for patients and the community. The seven-storey facility brings together cancer specialists, advanced diagnostics, treatment, clinical trials, navigation, supportive services and survivorship care in one dedicated environment designed around patients and families.
Once fully operational, the pavilion is expected to serve approximately 200,000 outpatient visits and 5,000 inpatient admissions annually, with 80 private inpatient beds.
With construction complete, UChicago Medicine will enter the final phase preparing the building to welcome patients, including outfitting clinical spaces, testing systems and workflows, and training teams to operate in the new environment.
AbbVie and Iambic agree collaboration for discovery and development of small molecule therapies
Grunenthal to acquire Stivarga cancer treatment
Precigen announces FDA platform technology designation for AdenoVerse
Enhertu recommended for EU approval in early HER2-positive breast cancer
PureTech receives FDA Fast Track designation for LYT-200 in HR-MDS
Coiled Therapeutics completes enrolment in two AO-252 formulation cohorts
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
GSK to acquire trispecific T cell-engager from Chimagen for multiple myeloma
Kelun-Biotech publishes phase III data for trastuzumab botidotin in HER2-positive breast cancer
AstraZeneca's Etcamah misses primary endpoint in Phase III breast cancer trial
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Akeso presents positive results from registrational Phase III study of ivonescimab
ABL Diagnostics files bid to acquire IntegraGen
Tyra Biosciences declares positive Phase 2 results for oral dabogratinib in bladder cancer